Commissioning of Helium Ion Therapy and the First Patient Treatment With Active Beam Delivery.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
15 Jul 2023
Historique:
received: 28 07 2022
revised: 22 11 2022
accepted: 09 01 2023
medline: 26 6 2023
pubmed: 22 1 2023
entrez: 21 1 2023
Statut: ppublish

Résumé

Helium ions offer intermediate physical and biological properties to the clinically used protons and carbon ions. This work presents the commissioning of the first clinical treatment planning system (TPS) for helium ion therapy with active beam delivery to prepare the first patients' treatment at the Heidelberg Ion-Beam Therapy Center (HIT). Through collaboration between RaySearch Laboratories and HIT, absorbed and relative biological effectiveness (RBE)-weighted calculation methods were integrated for helium ion beam therapy with raster-scanned delivery in the TPS RayStation. At HIT, a modified microdosimetric kinetic biological model was chosen as reference biological model. TPS absorbed dose predictions were compared against measurements with several devices, using phantoms of different complexities, from homogeneous to heterogeneous anthropomorphic phantoms. RBE and RBE-weighted dose predictions of the TPS were verified against calculations with an independent RBE-weighted dose engine. The patient-specific quality assurance of the first treatment at HIT using helium ion beam with raster-scanned delivery is presented considering standard patient-specific measurements in a water phantom and 2 independent dose calculations with a Monte Carlo or an analytical-based engine. TPS predictions were consistent with dosimetric measurements and independent dose engines computations for absorbed and RBE-weighted doses. The mean difference between dose measurements to the TPS calculation was 0.2% for spread-out Bragg peaks in water. Verification of the first patient treatment TPS predictions against independent engines for both absorbed and RBE-weighted doses presents differences within 2% in the target and with a maximum deviation of 3.5% in the investigated critical regions of interest. Helium ion beam therapy has been successfully commissioned and introduced into clinical use. Through comprehensive validation of the absorbed and RBE-weighted dose predictions of the RayStation TPS, the first clinical TPS for helium ion therapy using raster-scanned delivery was employed to plan the first helium patient treatment at HIT.

Identifiants

pubmed: 36681200
pii: S0360-3016(23)00055-X
doi: 10.1016/j.ijrobp.2023.01.015
pii:
doi:

Substances chimiques

Helium 206GF3GB41
Protons 0
Water 059QF0KO0R

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

935-948

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Thomas Tessonnier (T)

Heidelberg Ion-Beam Therapy Center, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology in the National Center for Radiation Oncology, Heidelberg, Germany.

Swantje Ecker (S)

Heidelberg Ion-Beam Therapy Center, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.

Judith Besuglow (J)

Clinical Cooperation Unit Radiation Oncology, National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology in the National Center for Radiation Oncology, Heidelberg, Germany; Division of Molecular and Translational Radiation Oncology, Department of Radiation Oncology, Heidelberg Faculty of Medicine and Heidelberg University Hospital, Heidelberg Ion-Beam Therapy Center, Heidelberg, Germany; Department of Physics and Astronomy, Heidelberg University, Germany.

Jakob Naumann (J)

Heidelberg Ion-Beam Therapy Center, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.

Stewart Mein (S)

Clinical Cooperation Unit Radiation Oncology, National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology in the National Center for Radiation Oncology, Heidelberg, Germany; Division of Molecular and Translational Radiation Oncology, Department of Radiation Oncology, Heidelberg Faculty of Medicine and Heidelberg University Hospital, Heidelberg Ion-Beam Therapy Center, Heidelberg, Germany; German Cancer Consortium Core-Center Heidelberg, German Cancer Research Center, Heidelberg, Germany.

Friderike K Longarino (FK)

Clinical Cooperation Unit Radiation Oncology, National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology in the National Center for Radiation Oncology, Heidelberg, Germany; Division of Molecular and Translational Radiation Oncology, Department of Radiation Oncology, Heidelberg Faculty of Medicine and Heidelberg University Hospital, Heidelberg Ion-Beam Therapy Center, Heidelberg, Germany; Department of Physics and Astronomy, Heidelberg University, Germany.

Malte Ellerbrock (M)

Heidelberg Ion-Beam Therapy Center, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.

Benjamin Ackermann (B)

Heidelberg Ion-Beam Therapy Center, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.

Marcus Winter (M)

Heidelberg Ion-Beam Therapy Center, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.

Stephan Brons (S)

Heidelberg Ion-Beam Therapy Center, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.

Abdallah Qubala (A)

Heidelberg Ion-Beam Therapy Center, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology in the National Center for Radiation Oncology, Heidelberg, Germany; Faculty of Medicine, University of Heidelberg, Heidelberg, Germany.

Thomas Haberer (T)

Heidelberg Ion-Beam Therapy Center, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.

Jürgen Debus (J)

Heidelberg Ion-Beam Therapy Center, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology in the National Center for Radiation Oncology, Heidelberg, Germany; Division of Molecular and Translational Radiation Oncology, Department of Radiation Oncology, Heidelberg Faculty of Medicine and Heidelberg University Hospital, Heidelberg Ion-Beam Therapy Center, Heidelberg, Germany; German Cancer Consortium Core-Center Heidelberg, German Cancer Research Center, Heidelberg, Germany.

Oliver Jäkel (O)

Heidelberg Ion-Beam Therapy Center, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology in the National Center for Radiation Oncology, Heidelberg, Germany; German Cancer Research Center, Heidelberg, Germany. Electronic address: Oliver.Jaekel@med.uni-heidelberg.de.

Andrea Mairani (A)

Heidelberg Ion-Beam Therapy Center, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology in the National Center for Radiation Oncology, Heidelberg, Germany; National Centre of Oncological Hadrontherapy, Medical Physics, Pavia, Italy. Electronic address: Andrea.Mairani@med.uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH